Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376866256> ?p ?o ?g. }
- W4376866256 endingPage "1112" @default.
- W4376866256 startingPage "1104" @default.
- W4376866256 abstract "This phase II study investigated whether durvalumab/tremelimumab with proton therapy improves the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) in heavily treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients.Patients who previously received more than one chemotherapy, including at least one platinum-based regimen, and who had at least two measurable lesions were enrolled. Patients received 1,500 mg durvalumab intravenously combined with 75 mg tremelimumab intravenously every 4 weeks for four cycles followed by 1,500 mg durvalumab every 4 weeks. After one cycle of the durvalumab/tremelimumab treatment, proton therapy was given with a total dose of 25 Gy in 5 Gy daily fractions to one of the measurable lesions. We also assessed the ORR in the target lesion outside the radiation field to evaluate the abscopal effect.Thirty-one patients were enrolled between March 2018 and July 2020. With 8.6 months of follow-up, the ORR was 22.6% (7/31), including one complete response and six partial responses. The median OS was 8.4 months (95% confidence interval [CI], 2.5 to 14.3) and the median PFS was 2.4 months (95% CI, 0.6 to 4.2). Among the 23 evaluable patients who completed proton therapy, the ORR was 30.4% (7/23). The median OS was 11.1 months (95% CI, 6.5 to 15.8), and the median PFS was 3.7 months (95% CI, 1.6 to 5.7). Grade 3 or higher adverse events were observed in six patients (19.4%) as follows: anemia (n=1), constipation (n=1), electrolyte imbalances (n=2), hyperglycemia (n=1), and pneumonia (n=1).The combination of durvalumab/tremelimuab with proton therapy was tolerated well and had encouraging anti-tumor efficacy in non-irradiated tumor lesions of heavily treated HNSCC patients." @default.
- W4376866256 created "2023-05-18" @default.
- W4376866256 creator A5004474010 @default.
- W4376866256 creator A5013257516 @default.
- W4376866256 creator A5017982180 @default.
- W4376866256 creator A5030107272 @default.
- W4376866256 creator A5034739279 @default.
- W4376866256 creator A5074002434 @default.
- W4376866256 creator A5081560950 @default.
- W4376866256 creator A5090552664 @default.
- W4376866256 date "2023-10-15" @default.
- W4376866256 modified "2023-10-15" @default.
- W4376866256 title "Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma" @default.
- W4376866256 cites W2015186160 @default.
- W4376866256 cites W2030395337 @default.
- W4376866256 cites W2066671159 @default.
- W4376866256 cites W2095148496 @default.
- W4376866256 cites W2112845420 @default.
- W4376866256 cites W2117878645 @default.
- W4376866256 cites W2118991777 @default.
- W4376866256 cites W2123176392 @default.
- W4376866256 cites W2133739473 @default.
- W4376866256 cites W2140231263 @default.
- W4376866256 cites W2260067559 @default.
- W4376866256 cites W2529484692 @default.
- W4376866256 cites W2621240220 @default.
- W4376866256 cites W2799372507 @default.
- W4376866256 cites W2802454361 @default.
- W4376866256 cites W2893824814 @default.
- W4376866256 cites W2896764227 @default.
- W4376866256 cites W2898717093 @default.
- W4376866256 cites W2943902312 @default.
- W4376866256 cites W2969612771 @default.
- W4376866256 cites W2971480237 @default.
- W4376866256 cites W2980537150 @default.
- W4376866256 cites W3015755028 @default.
- W4376866256 cites W3080889076 @default.
- W4376866256 cites W3093708469 @default.
- W4376866256 cites W3104676857 @default.
- W4376866256 cites W3197047635 @default.
- W4376866256 cites W4226395090 @default.
- W4376866256 doi "https://doi.org/10.4143/crt.2023.502" @default.
- W4376866256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37202212" @default.
- W4376866256 hasPublicationYear "2023" @default.
- W4376866256 type Work @default.
- W4376866256 citedByCount "2" @default.
- W4376866256 countsByYear W43768662562023 @default.
- W4376866256 crossrefType "journal-article" @default.
- W4376866256 hasAuthorship W4376866256A5004474010 @default.
- W4376866256 hasAuthorship W4376866256A5013257516 @default.
- W4376866256 hasAuthorship W4376866256A5017982180 @default.
- W4376866256 hasAuthorship W4376866256A5030107272 @default.
- W4376866256 hasAuthorship W4376866256A5034739279 @default.
- W4376866256 hasAuthorship W4376866256A5074002434 @default.
- W4376866256 hasAuthorship W4376866256A5081560950 @default.
- W4376866256 hasAuthorship W4376866256A5090552664 @default.
- W4376866256 hasBestOaLocation W43768662561 @default.
- W4376866256 hasConcept C121608353 @default.
- W4376866256 hasConcept C126322002 @default.
- W4376866256 hasConcept C141071460 @default.
- W4376866256 hasConcept C143998085 @default.
- W4376866256 hasConcept C2776530083 @default.
- W4376866256 hasConcept C2776833033 @default.
- W4376866256 hasConcept C2777701055 @default.
- W4376866256 hasConcept C2777742743 @default.
- W4376866256 hasConcept C2778424827 @default.
- W4376866256 hasConcept C2778650287 @default.
- W4376866256 hasConcept C2780030458 @default.
- W4376866256 hasConcept C2781413609 @default.
- W4376866256 hasConcept C2781433595 @default.
- W4376866256 hasConcept C509974204 @default.
- W4376866256 hasConcept C71924100 @default.
- W4376866256 hasConceptScore W4376866256C121608353 @default.
- W4376866256 hasConceptScore W4376866256C126322002 @default.
- W4376866256 hasConceptScore W4376866256C141071460 @default.
- W4376866256 hasConceptScore W4376866256C143998085 @default.
- W4376866256 hasConceptScore W4376866256C2776530083 @default.
- W4376866256 hasConceptScore W4376866256C2776833033 @default.
- W4376866256 hasConceptScore W4376866256C2777701055 @default.
- W4376866256 hasConceptScore W4376866256C2777742743 @default.
- W4376866256 hasConceptScore W4376866256C2778424827 @default.
- W4376866256 hasConceptScore W4376866256C2778650287 @default.
- W4376866256 hasConceptScore W4376866256C2780030458 @default.
- W4376866256 hasConceptScore W4376866256C2781413609 @default.
- W4376866256 hasConceptScore W4376866256C2781433595 @default.
- W4376866256 hasConceptScore W4376866256C509974204 @default.
- W4376866256 hasConceptScore W4376866256C71924100 @default.
- W4376866256 hasFunder F4320307770 @default.
- W4376866256 hasIssue "4" @default.
- W4376866256 hasLocation W43768662561 @default.
- W4376866256 hasLocation W43768662562 @default.
- W4376866256 hasOpenAccess W4376866256 @default.
- W4376866256 hasPrimaryLocation W43768662561 @default.
- W4376866256 hasRelatedWork W2188594974 @default.
- W4376866256 hasRelatedWork W2794851837 @default.
- W4376866256 hasRelatedWork W2890051926 @default.
- W4376866256 hasRelatedWork W2981744924 @default.
- W4376866256 hasRelatedWork W3005499534 @default.